Breaking News Instant updates and real-time market news.

LJPC

La Jolla

$38.44

2.56 (7.13%)

16:01
03/20/17
03/20
16:01
03/20/17
16:01

La Jolla files to sell $100M of common stock

La Jolla intends to use the net proceeds from the underwritten offering for general corporate purposes, including funding its ongoing and future clinical trials of its drug candidates, for expenses relating to the potential regulatory approval of LJPC-501, potential future acquisitions and for general and administrative expenses. J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.

  • 20

    Mar

LJPC La Jolla
$38.44

2.56 (7.13%)

02/27/17
JEFF
02/27/17
NO CHANGE
Target $40
JEFF
Buy
La Jolla price target raised to $40 from $27 at Jefferies
Jefferies analyst Eun Yang raised her price target for La Jolla Pharmaceutical to $40 after the company announced positive top-line results from the Phase 3 study of LJPC-501 in patients with catecholamine resistant hypotension. The stock in afternoon trading is up 82%, or $16.36, to $36.23. While a positive outcome was largely expected, a trend toward mortality benefit is encouraging and unexpected, Yang tells investors in a research note, citing her discussions with experts. Her new price target reflects 100% probability for LJPC-501 clinical success and pricing at parity to other hospital-based drugs. Yang keeps a Buy rating on La Jolla.
02/27/17
COWN
02/27/17
NO CHANGE
Target $55
COWN
Outperform
La Jolla price target raised to $55 from $40 at Cowen
Cowen analyst Phil Nadeau raised La Jolla's price target to $55 from $40 following compelling LJPC-501 data in its SPA-supported Phase III ATHOS-3 trial. The analyst believes the data de-risks LJPC-501 and expects the company to file for FDA approval in 2H 2017. Nadeau has a Buy rating on La Jolla shares.
02/28/17
RHCO
02/28/17
NO CHANGE
RHCO
La Jolla data positive, says SunTrust
SunTrust analyst Yatin Suneja believes that data on La Jolia's LJPC-501 was "highly favorable," supports its approval and suggests that it could become the standard of care in last-line CRH. The analyst thinks that the drug represents an opportunity of at least $500M, and he raised his price target on the name to $57 from $38 while keeping a Buy rating.
03/10/17
CHDN
03/10/17
NO CHANGE
Target $90
CHDN
Buy
Chardan has increased confidence in Top Pick La Jolla
Chardan said it has increased confidence in Top Pick La Jolla Pharmaceutica following meetings wit CEO, George F. Tidmarsh, MD, PhD, while the company was on a roadshow to meet with investors and analysts. The firm's analyst came away from the meeting more positive on the company's de-risked strategy towards drug development, and believes the potential of the strategy is supported by the recent success of LJPC-501 in catecholamine resistant hypotension in its pivotal phase III study, ATHOS-3.

TODAY'S FREE FLY STORIES

GPK

Graphic Packaging

$13.77

0.04 (0.29%)

06:33
07/25/17
07/25
06:33
07/25/17
06:33
Earnings
Graphic Packaging reports Q2 adj. EPS 15c, consensus 15c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

PHM

PulteGroup

$24.42

0.11 (0.45%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Hot Stocks
Breaking Hot Stocks news story on PulteGroup »

PulteGroup believes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SVU

Supervalu

$3.25

-0.01 (-0.31%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Earnings
Supervalu reports Q1 adjusted EPS 9c, consensus 11c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MORE

Monogram Residential Trust

$11.95

0.01 (0.08%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Downgrade
Monogram Residential Trust rating change  »

Monogram Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$24.42

0.11 (0.45%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Earnings
PulteGroup reports Q2 adjusted EPS 47c, consensus 41c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TEAM

Atlassian

$36.41

0.66 (1.85%)

06:31
07/25/17
07/25
06:31
07/25/17
06:31
Upgrade
Atlassian rating change  »

Atlassian upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

BIIB

Biogen

$284.70

1.78 (0.63%)

06:31
07/25/17
07/25
06:31
07/25/17
06:31
Earnings
Biogen reports Q2 adjusted EPS $5.04, consensus $4.41 »

Reports Q2 revenue $3.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

GOOG

Alphabet

$980.34

7.42 (0.76%)

, GOOGL

Alphabet Class A

$998.31

4.47 (0.45%)

06:30
07/25/17
07/25
06:30
07/25/17
06:30
Recommendations
Alphabet, Alphabet Class A analyst commentary  »

Alphabet earnings…

GOOG

Alphabet

$980.34

7.42 (0.76%)

GOOGL

Alphabet Class A

$998.31

4.47 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$84.74

0.08 (0.09%)

06:30
07/25/17
07/25
06:30
07/25/17
06:30
Hot Stocks
Eli Lilly will pursue new standard-of-care changing therapies in oncology »

Eli Lilly is providing an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 11

    Sep

LLY

Eli Lilly

$84.74

0.08 (0.09%)

06:29
07/25/17
07/25
06:29
07/25/17
06:29
Earnings
Eli Lilly raises FY17 EPS view to $4.10-$4.20 from $4.05-$4.15, consensus $4.12 »

Raises FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 11

    Sep

DDAIF

Daimler AG

$71.00

-1.9399 (-2.66%)

, BMWYY

BMW

$30.72

-0.8 (-2.54%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Periodicals
Daimler directors to discuss alleged German auto cartel, Reuters says »

Daimler's (DDAIF)…

DDAIF

Daimler AG

$71.00

-1.9399 (-2.66%)

BMWYY

BMW

$30.72

-0.8 (-2.54%)

VLKAY

Volkswagen

$32.19

-0.79 (-2.40%)

POAHY

Porsche

$5.82

-0.03 (-0.51%)

AUDVF

Audi AG

$835.60

-4.8 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WERN

Werner

$29.20

-0.35 (-1.18%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Upgrade
Werner rating change  »

Werner upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

TNTR

Tintri

$6.95

0.16 (2.36%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Initiation
Tintri initiated  »

Tintri initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BY

Byline Bancorp

$20.85

0.13 (0.63%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Initiation
Byline Bancorp initiated  »

Byline Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

LLY

Eli Lilly

$84.74

0.08 (0.09%)

06:26
07/25/17
07/25
06:26
07/25/17
06:26
Earnings
Eli Lilly reports Q2 EPS $1.11, consensus $1.05 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 11

    Sep

NCMGY

Newcrest Mining

$15.72

0.12 (0.77%)

06:26
07/25/17
07/25
06:26
07/25/17
06:26
Upgrade
Newcrest Mining rating change  »

Newcrest Mining upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPNC

Spectranetics

$38.50

0.05 (0.13%)

06:21
07/25/17
07/25
06:21
07/25/17
06:21
Downgrade
Spectranetics rating change  »

Spectranetics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMP

Tompkins Financial

$78.41

-0.14 (-0.18%)

06:21
07/25/17
07/25
06:21
07/25/17
06:21
Upgrade
Tompkins Financial rating change  »

Tompkins Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNE

Sony

$40.61

-0.2 (-0.49%)

, AAPL

Apple

$152.09

1.82 (1.21%)

06:20
07/25/17
07/25
06:20
07/25/17
06:20
Periodicals
Sony restructures television production unit, WSJ reports »

Sony Pictures…

SNE

Sony

$40.61

-0.2 (-0.49%)

AAPL

Apple

$152.09

1.82 (1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

LLY

Eli Lilly

$84.74

0.08 (0.09%)

, INCY

Incyte

$138.27

4.05 (3.02%)

06:20
07/25/17
07/25
06:20
07/25/17
06:20
Hot Stocks
Eli Lilly, Incyte resubmit baricitinib NDA to FDA »

Eli Lilly (LLY) and…

LLY

Eli Lilly

$84.74

0.08 (0.09%)

INCY

Incyte

$138.27

4.05 (3.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

  • 11

    Sep

SSB

South State

$83.90

0.7 (0.84%)

06:19
07/25/17
07/25
06:19
07/25/17
06:19
Upgrade
South State rating change  »

South State upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 18

    Sep

BSRR

Sierra Bancorp

$24.15

0.34 (1.43%)

06:19
07/25/17
07/25
06:19
07/25/17
06:19
Upgrade
Sierra Bancorp rating change  »

Sierra Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

BY

Byline Bancorp

$20.85

0.13 (0.63%)

06:17
07/25/17
07/25
06:17
07/25/17
06:17
Initiation
Byline Bancorp initiated  »

Byline Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

GOOGL

Alphabet Class A

$998.31

4.47 (0.45%)

, GOOG

Alphabet

$980.34

7.42 (0.76%)

06:16
07/25/17
07/25
06:16
07/25/17
06:16
Recommendations
Alphabet Class A, Alphabet analyst commentary  »

Alphabet post-earnings…

GOOGL

Alphabet Class A

$998.31

4.47 (0.45%)

GOOG

Alphabet

$980.34

7.42 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LULU

lululemon

$62.02

0.08 (0.13%)

06:16
07/25/17
07/25
06:16
07/25/17
06:16
Downgrade
lululemon rating change  »

lululemon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.